Oncodrug is an innovative multi-disciplinary drug discovery biotech targeting oncology, fibrotic and metabolic diseases of high unmet need.
Integrated
Drug Discovery
From target validation to candidate nomination – our comprehensive in-house capabilities advance drug discovery.
OUR SCIENCE
Focus Areas
Oncodrug R&D focuses on underexplored targets of high medical importance.
LOX inhibitors target collagen crosslinking, a key process in the pathogenesis of a wide range of fibrotic diseases and a major driver of cancer treatment resistance.
Learn More→
ALDH1A3 inhibitors attenuate the retinoic acid receptor pathway to restore pancreatic β-cell function in type II diabetes and to overcome cancer treatment resistance.
Learn More→
Inhibitors of PKN2, an exciting new biological target, overcome RAS and EGFR inhibitors resistance in targeted therapies and are new tools to mitigate heart failure.
Learn More→
Oncodrug VI targets cancers with a unique combination of mechanisms of action.
Learn More→
R&D PORTFOLIO
Our Pipeline
Oncodrug has multiple drug discovery assets ranging from small molecules to biologics.
Click the image above to enlarge
Expertise
Our Capabilities
Oncodrug’s multidisciplinary in-house capabilities ensure swift and cost-effective drug discovery.
OUR TEAM
Experienced Leadership
Oncodrug is led by drug discovery experts with proven track records in progressing projects from target validation through to clinical trials.
Founder & CEO
Caroline has over 30 years experience in drug discovery and translational research…
Founder & CSO
Richard has over 30 years of experience in cell signalling, cancer biology and translational research…
Advisor
Mr Julian H Lewis is advisor to the Oncodrug Board. He is on the Board of Directors at Lewis Foundation…
Head of Chemistry
Dan has over 30 years of experience in medicinal chemistry and drug discovery, along with substantial expertise in…
Head of Discovery
Leo has over 20 years of experience in drug discovery. Prior to joining Oncodrug, he has worked in the CRUK Manchester Institute…
WORK WITH US
Investor & Partnership Enquiries
Interested in investing or partnering with us?
Please reach out.
LATEST
News & Updates
